NO830669L - Nye glykoproteiner, fremgangsmaater for deres fremstilling og terapeutiske preparater for tumorer som inneholder slike glykoproteiner - Google Patents
Nye glykoproteiner, fremgangsmaater for deres fremstilling og terapeutiske preparater for tumorer som inneholder slike glykoproteinerInfo
- Publication number
- NO830669L NO830669L NO830669A NO830669A NO830669L NO 830669 L NO830669 L NO 830669L NO 830669 A NO830669 A NO 830669A NO 830669 A NO830669 A NO 830669A NO 830669 L NO830669 L NO 830669L
- Authority
- NO
- Norway
- Prior art keywords
- cells
- reaction
- shows
- phosphate buffer
- hours
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 65
- 206010028980 Neoplasm Diseases 0.000 title claims description 31
- 108090000288 Glycoproteins Proteins 0.000 title claims description 28
- 102000003886 Glycoproteins Human genes 0.000 title claims description 28
- 238000002360 preparation method Methods 0.000 title description 20
- 230000001225 therapeutic effect Effects 0.000 title description 3
- 210000004027 cell Anatomy 0.000 claims description 226
- 241001465754 Metazoa Species 0.000 claims description 73
- 238000006243 chemical reaction Methods 0.000 claims description 57
- 230000000694 effects Effects 0.000 claims description 48
- 235000000346 sugar Nutrition 0.000 claims description 44
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 30
- 239000006228 supernatant Substances 0.000 claims description 30
- 210000004881 tumor cell Anatomy 0.000 claims description 30
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 29
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 27
- 239000008363 phosphate buffer Substances 0.000 claims description 27
- 239000007864 aqueous solution Substances 0.000 claims description 24
- 241000282412 Homo Species 0.000 claims description 23
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 229920005654 Sephadex Polymers 0.000 claims description 19
- 239000012507 Sephadex™ Substances 0.000 claims description 19
- 210000004698 lymphocyte Anatomy 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 15
- 239000000243 solution Substances 0.000 claims description 15
- 150000008163 sugars Chemical class 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 12
- 239000000411 inducer Substances 0.000 claims description 12
- 208000032839 leukemia Diseases 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 11
- 230000003013 cytotoxicity Effects 0.000 claims description 11
- 231100000135 cytotoxicity Toxicity 0.000 claims description 11
- 238000009792 diffusion process Methods 0.000 claims description 10
- 210000002950 fibroblast Anatomy 0.000 claims description 10
- 238000002523 gelfiltration Methods 0.000 claims description 10
- 150000008273 hexosamines Chemical class 0.000 claims description 10
- 150000002402 hexoses Chemical class 0.000 claims description 10
- 230000003307 reticuloendothelial effect Effects 0.000 claims description 10
- 125000005629 sialic acid group Chemical group 0.000 claims description 10
- 239000012475 sodium chloride buffer Substances 0.000 claims description 10
- 239000012064 sodium phosphate buffer Substances 0.000 claims description 10
- 240000003864 Ulex europaeus Species 0.000 claims description 9
- 235000010730 Ulex europaeus Nutrition 0.000 claims description 9
- 150000001413 amino acids Chemical class 0.000 claims description 9
- 230000000259 anti-tumor effect Effects 0.000 claims description 9
- 101710186708 Agglutinin Proteins 0.000 claims description 7
- 101710146024 Horcolin Proteins 0.000 claims description 7
- 101710189395 Lectin Proteins 0.000 claims description 7
- 101710179758 Mannose-specific lectin Proteins 0.000 claims description 7
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 claims description 7
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 claims description 7
- 239000000910 agglutinin Substances 0.000 claims description 7
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 claims description 7
- 241000699800 Cricetinae Species 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 6
- 210000002540 macrophage Anatomy 0.000 claims description 6
- 201000001441 melanoma Diseases 0.000 claims description 6
- 102000016605 B-Cell Activating Factor Human genes 0.000 claims description 5
- 108010028006 B-Cell Activating Factor Proteins 0.000 claims description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 5
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 5
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 5
- 230000007062 hydrolysis Effects 0.000 claims description 5
- 238000006460 hydrolysis reaction Methods 0.000 claims description 5
- 241000894007 species Species 0.000 claims description 5
- MYKOKMFESWKQRX-UHFFFAOYSA-N 10h-anthracen-9-one;sulfuric acid Chemical compound OS(O)(=O)=O.C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 MYKOKMFESWKQRX-UHFFFAOYSA-N 0.000 claims description 4
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 claims description 4
- 210000001124 body fluid Anatomy 0.000 claims description 4
- 239000010839 body fluid Substances 0.000 claims description 4
- 230000004069 differentiation Effects 0.000 claims description 4
- HHIVCXLCMPHUSC-UHFFFAOYSA-N hydron;1h-indol-1-ium;sulfate Chemical compound OS(O)(=O)=O.C1=CC=C2NC=CC2=C1 HHIVCXLCMPHUSC-UHFFFAOYSA-N 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 239000001117 sulphuric acid Substances 0.000 claims description 4
- 238000001502 gel electrophoresis Methods 0.000 claims description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 2
- 238000004255 ion exchange chromatography Methods 0.000 claims description 2
- 108020001775 protein parts Proteins 0.000 claims description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- 102100029469 WD repeat and HMG-box DNA-binding protein 1 Human genes 0.000 claims 1
- 101710097421 WD repeat and HMG-box DNA-binding protein 1 Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- 239000001963 growth medium Substances 0.000 description 29
- 239000002609 medium Substances 0.000 description 29
- 241000699670 Mus sp. Species 0.000 description 28
- 102100032919 Chromobox protein homolog 1 Human genes 0.000 description 24
- 101000797584 Homo sapiens Chromobox protein homolog 1 Proteins 0.000 description 24
- 238000002347 injection Methods 0.000 description 21
- 239000007924 injection Substances 0.000 description 21
- 239000012298 atmosphere Substances 0.000 description 19
- 210000002966 serum Anatomy 0.000 description 19
- 244000309466 calf Species 0.000 description 17
- 239000000203 mixture Substances 0.000 description 17
- 102100032920 Chromobox protein homolog 2 Human genes 0.000 description 14
- 101000797586 Homo sapiens Chromobox protein homolog 2 Proteins 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 102100037676 CCAAT/enhancer-binding protein zeta Human genes 0.000 description 13
- 101710104127 CCAAT/enhancer-binding protein zeta Proteins 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 11
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 11
- 230000001472 cytotoxic effect Effects 0.000 description 11
- 230000004083 survival effect Effects 0.000 description 10
- 239000012153 distilled water Substances 0.000 description 9
- 238000002054 transplantation Methods 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 238000005303 weighing Methods 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 230000008105 immune reaction Effects 0.000 description 7
- 239000002504 physiological saline solution Substances 0.000 description 7
- 108010047620 Phytohemagglutinins Proteins 0.000 description 6
- 210000005260 human cell Anatomy 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- 230000003287 optical effect Effects 0.000 description 6
- 230000001885 phytohemagglutinin Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 231100000433 cytotoxic Toxicity 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 5
- 239000003889 eye drop Substances 0.000 description 5
- 238000002329 infrared spectrum Methods 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000007923 nasal drop Substances 0.000 description 5
- 229940100662 nasal drops Drugs 0.000 description 5
- 102000003390 tumor necrosis factor Human genes 0.000 description 5
- 206010067484 Adverse reaction Diseases 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- -1 CBxl Proteins 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 4
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 4
- 235000011130 ammonium sulphate Nutrition 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 229940127089 cytotoxic agent Drugs 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 229920001592 potato starch Polymers 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 125000003003 spiro group Chemical group 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 3
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 229940012356 eye drops Drugs 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000002955 immunomodulating agent Substances 0.000 description 3
- 238000001155 isoelectric focusing Methods 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000004445 quantitative analysis Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108010062580 Concanavalin A Proteins 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- 208000003468 Ehrlich Tumor Carcinoma Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010027458 Metastases to lung Diseases 0.000 description 2
- PPQNQXQZIWHJRB-UHFFFAOYSA-N Methylcholanthrene Chemical compound C1=CC=C2C3=CC4=CC=C(C)C(CC5)=C4C5=C3C=CC2=C1 PPQNQXQZIWHJRB-UHFFFAOYSA-N 0.000 description 2
- 241000711408 Murine respirovirus Species 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 101100020289 Xenopus laevis koza gene Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003145 cytotoxic factor Substances 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 239000002662 enteric coated tablet Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 210000003200 peritoneal cavity Anatomy 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 239000006215 rectal suppository Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 102100032902 Chromobox protein homolog 3 Human genes 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 241000272201 Columbiformes Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 101100421425 Drosophila melanogaster Sply gene Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 210000000712 G cell Anatomy 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101000797578 Homo sapiens Chromobox protein homolog 3 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 208000008342 Leukemia P388 Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 241000577979 Peromyscus spicilegus Species 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000006268 Sarcoma 180 Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 241000219871 Ulex Species 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000005422 blasting Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- HFOJRTIFHRRHGA-UHFFFAOYSA-N naphthalen-1-ol;sulfuric acid Chemical compound OS(O)(=O)=O.C1=CC=C2C(O)=CC=CC2=C1 HFOJRTIFHRRHGA-UHFFFAOYSA-N 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 108010016297 plasmin drug combination deoxyribonuclease Proteins 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 238000011046 pyrogen test Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/806—Antigenic peptides or proteins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
- Y10S530/809—Fused cells, e.g. hybridoma
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/828—Cancer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57028992A JPS58148826A (ja) | 1982-02-26 | 1982-02-26 | 糖蛋白質および腫瘍治療剤 |
| JP57028993A JPS58146293A (ja) | 1982-02-26 | 1982-02-26 | 抗腫瘍性糖蛋白質の製造方法 |
| JP57087674A JPS58203917A (ja) | 1982-05-24 | 1982-05-24 | 糖蛋白質およびその製法ならびに腫瘍治療剤 |
| JP57087675A JPS58203918A (ja) | 1982-05-24 | 1982-05-24 | 糖蛋白質およびその製造法ならびに腫瘍治療剤 |
| JP57108046A JPS58225024A (ja) | 1982-06-23 | 1982-06-23 | 糖蛋白質およびその製造方法ならびに腫瘍治療剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO830669L true NO830669L (no) | 1983-08-29 |
Family
ID=27521092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO830669A NO830669L (no) | 1982-02-26 | 1983-02-25 | Nye glykoproteiner, fremgangsmaater for deres fremstilling og terapeutiske preparater for tumorer som inneholder slike glykoproteiner |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US4481137A (fi) |
| BE (1) | BE896027A (fi) |
| BR (1) | BR8300933A (fi) |
| DD (1) | DD209634A5 (fi) |
| DE (1) | DE3306297A1 (fi) |
| DK (1) | DK93383A (fi) |
| FI (1) | FI830638L (fi) |
| FR (1) | FR2522267A1 (fi) |
| GB (1) | GB2117385B (fi) |
| GR (1) | GR78097B (fi) |
| LU (1) | LU84662A1 (fi) |
| NL (1) | NL8300727A (fi) |
| NO (1) | NO830669L (fi) |
| PL (1) | PL240784A1 (fi) |
| PT (1) | PT76296B (fi) |
| RO (1) | RO85901B (fi) |
| SE (1) | SE8301073L (fi) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4920196A (en) * | 1982-07-30 | 1990-04-24 | Genentech, Inc. | Human lymphotoxin |
| DE3334405A1 (de) * | 1983-09-23 | 1985-04-04 | Behringwerke Ag, 3550 Marburg | Membranassoziierte proteine (mp(pfeil abwaerts)2(pfeil abwaerts)), verfahren zu ihrer gewinnung sowie ihre verwendung |
| JPS60112718A (ja) * | 1983-11-21 | 1985-06-19 | Kyorin Pharmaceut Co Ltd | 抗腫瘍作用を示す蛋白性物質及びその製造方法 |
| US4758549A (en) * | 1983-12-13 | 1988-07-19 | Kabushiki Kaisha Mayashibara Seibutsu Kagaku Kenkyujo | Lymphokine, monoclonal antibody specific to the lymphokine and their production and uses |
| US4879226A (en) * | 1984-04-06 | 1989-11-07 | Asahi Kasei Kogyo Kabushiki Kaisha | Novel human physiologically active polypeptide |
| US5683688A (en) | 1984-05-31 | 1997-11-04 | Genentech, Inc. | Unglycosylated recombinant human lymphotoxin polypeptides and compositions |
| US4959457A (en) * | 1984-05-31 | 1990-09-25 | Genentech, Inc. | Anti-lymphotoxin |
| US5672347A (en) * | 1984-07-05 | 1997-09-30 | Genentech, Inc. | Tumor necrosis factor antagonists and their use |
| US6686455B1 (en) | 1984-07-05 | 2004-02-03 | Genentech, Inc. | Tumor necrosis factor |
| FR2568125B1 (fr) * | 1984-07-25 | 1988-04-15 | Kogo Michiko | Agent anti-tumeur contenant la proteine du sucre |
| US5019385A (en) * | 1984-11-09 | 1991-05-28 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Novel lymphopine LK 2 and pharmaceutic compositions containing same |
| JPH0631318B2 (ja) * | 1985-09-18 | 1994-04-27 | 株式会社林原生物化学研究所 | 新リンホカインｉｉｉとその製法 |
| US4822605A (en) * | 1986-02-18 | 1989-04-18 | Exovir, Inc. | Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like |
| AU630106B2 (en) * | 1988-07-15 | 1992-10-22 | Trustees Of Columbia University In The City Of New York, The | Tumor necrosis enhancing factor and methods of preparation and use |
| US5106745A (en) * | 1989-12-06 | 1992-04-21 | Board Of Regents, The University Of Texas System | Broad spectrum virus inhibitor, UTI-β |
| JP3552240B2 (ja) * | 1993-02-23 | 2004-08-11 | 第一製薬株式会社 | 高濃度ｔｃｆ製剤 |
| US5641867A (en) * | 1993-09-29 | 1997-06-24 | The Trustees Of Columbia University In The City Of New York | Antibody which specifically binds to endothelial-monocyte activating polypeptide II |
| JP4006058B2 (ja) * | 1997-03-11 | 2007-11-14 | 第一三共株式会社 | 多臓器不全予防及び／又は治療剤 |
| DK0950416T3 (da) * | 1997-03-14 | 2007-02-26 | Daiichi Seiyaku Co | Anvendelse af TCF-II til behandling af cancerrelateret tab af kropsvægt, anæmi og TNF-forhöjelse |
| BG65084B1 (bg) * | 2002-03-13 | 2007-02-28 | Закрьiтое Акционерное Общество, Производственное Предприятие"Эндо-Фарм-А" | Нов клас биоактивни гликопротеини |
| AU2004273783A1 (en) * | 2003-07-12 | 2005-03-31 | Accelr8 Technology Corporation | Sensitive and rapid biodetection |
| US7341841B2 (en) * | 2003-07-12 | 2008-03-11 | Accelr8 Technology Corporation | Rapid microbial detection and antimicrobial susceptibility testing |
| US20120077206A1 (en) | 2003-07-12 | 2012-03-29 | Accelr8 Technology Corporation | Rapid Microbial Detection and Antimicrobial Susceptibility Testing |
| US10254204B2 (en) | 2011-03-07 | 2019-04-09 | Accelerate Diagnostics, Inc. | Membrane-assisted purification |
| ES2551922T3 (es) | 2011-03-07 | 2015-11-24 | Accelerate Diagnostics, Inc. | Sistemas rápidos de purificación celular |
| US9677109B2 (en) | 2013-03-15 | 2017-06-13 | Accelerate Diagnostics, Inc. | Rapid determination of microbial growth and antimicrobial susceptibility |
| US10253355B2 (en) | 2015-03-30 | 2019-04-09 | Accelerate Diagnostics, Inc. | Instrument and system for rapid microorganism identification and antimicrobial agent susceptibility testing |
| EP3278115A2 (en) | 2015-03-30 | 2018-02-07 | Accelerate Diagnostics, Inc. | Instrument and system for rapid microorganism identification and antimicrobial agent susceptibility testing |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2726886A1 (de) * | 1977-06-15 | 1979-01-18 | Behringwerke Ag | Neues glykoprotein und verfahren zu dessen herstellung |
| JPS6030291B2 (ja) * | 1978-03-20 | 1985-07-16 | 森永乳業株式会社 | 人顆粒球の分化増殖を促進するｈｇｉ糖蛋白質、ｈｇｉ糖蛋白質の製造法及びｈｇｉ糖蛋白質を含有する白血球減少症治療剤 |
| US4261976A (en) * | 1978-10-03 | 1981-04-14 | The Massachusetts General Hospital | Method and glycoprotein composition for inhibition of growth of transformed cells and tumors |
| US4243582A (en) * | 1979-04-26 | 1981-01-06 | Monsanto Company | Novel glycoproteins from bovine cartilage |
-
1983
- 1983-02-18 US US06/467,840 patent/US4481137A/en not_active Expired - Fee Related
- 1983-02-23 DE DE19833306297 patent/DE3306297A1/de not_active Withdrawn
- 1983-02-24 GR GR70607A patent/GR78097B/el unknown
- 1983-02-25 LU LU84662A patent/LU84662A1/fr unknown
- 1983-02-25 BR BR8300933A patent/BR8300933A/pt unknown
- 1983-02-25 BE BE210211A patent/BE896027A/fr not_active IP Right Cessation
- 1983-02-25 NL NL8300727A patent/NL8300727A/nl not_active Application Discontinuation
- 1983-02-25 DK DK93383A patent/DK93383A/da not_active Application Discontinuation
- 1983-02-25 PT PT76296A patent/PT76296B/pt unknown
- 1983-02-25 PL PL83240784A patent/PL240784A1/xx unknown
- 1983-02-25 FI FI830638A patent/FI830638L/fi not_active Application Discontinuation
- 1983-02-25 SE SE8301073A patent/SE8301073L/xx not_active Application Discontinuation
- 1983-02-25 NO NO830669A patent/NO830669L/no unknown
- 1983-02-25 GB GB08305330A patent/GB2117385B/en not_active Expired
- 1983-02-26 RO RO110170A patent/RO85901B/ro unknown
- 1983-02-28 DD DD83248327A patent/DD209634A5/de unknown
- 1983-02-28 FR FR8303274A patent/FR2522267A1/fr not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| LU84662A1 (fr) | 1983-09-08 |
| PT76296B (en) | 1985-11-12 |
| US4481137A (en) | 1984-11-06 |
| DK93383D0 (da) | 1983-02-25 |
| DE3306297A1 (de) | 1983-09-15 |
| GB2117385B (en) | 1985-05-09 |
| PL240784A1 (en) | 1983-11-07 |
| GR78097B (fi) | 1984-09-26 |
| GB2117385A (en) | 1983-10-12 |
| GB8305330D0 (en) | 1983-03-30 |
| NL8300727A (nl) | 1983-09-16 |
| FR2522267A1 (fr) | 1983-09-02 |
| BR8300933A (pt) | 1983-11-16 |
| FI830638A0 (fi) | 1983-02-25 |
| DK93383A (da) | 1983-08-27 |
| RO85901B (ro) | 1985-01-30 |
| BE896027A (fr) | 1983-08-25 |
| RO85901A (ro) | 1985-01-24 |
| DD209634A5 (de) | 1984-05-16 |
| SE8301073L (sv) | 1983-08-27 |
| FI830638L (fi) | 1983-08-27 |
| SE8301073D0 (sv) | 1983-02-25 |
| PT76296A (en) | 1983-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO830669L (no) | Nye glykoproteiner, fremgangsmaater for deres fremstilling og terapeutiske preparater for tumorer som inneholder slike glykoproteiner | |
| Sugimura et al. | Carcinogenic action of N-methyl-N′-nitro-N-nitrosoguanidine | |
| DK169479B1 (da) | Fremgangsmåde til fremstilling af humanspecifikt type II-interferon | |
| US4571336A (en) | Immune stimulation | |
| EP0159276A2 (en) | Substantially purified tumor growth inhibitory factor (tif) | |
| Fuhrman et al. | Toxins from eggs of fishes and amphibia | |
| US5187260A (en) | Process for the preparation of a high purity protamine-DNA complex and process for use of same | |
| Chang et al. | Cellular immunity of mice to Leishmania donovani in vitro: lymphokine-mediated killing of intracellular parasites in macrophages. | |
| Mendez et al. | Effects of concanavalin A, fed as a constituent of Jack bean (Canavalia ensiformis L.) seeds, on the humoral immune response and performance of broiler chickens | |
| US4180627A (en) | Process for in vivo transfer of cell-mediated immunity in mammals with alcoholic precipitates of Bovine Transfer factor | |
| KR930004596B1 (ko) | 신규 림포킨(lymphokine) 및 이에 대해 특이성을 갖는 모노클로날(monoclonal) 항체의 제조 방법 | |
| JPS6011890B2 (ja) | ツモアネクロシスフアクタ−の製造方法 | |
| US4442087A (en) | Interferon inducer, a process for producing the same and pharmaceutical composition containing the same | |
| EP1017406B1 (en) | Bovine excretion extracts having anticancer and anti-inflammatory activity and process for preparing the same | |
| CN114209812B (zh) | α-苦瓜素在制备抗炎药物中的用途 | |
| KR950008569B1 (ko) | 신규 림포카인(lymphokine) 및 그 제조방법과 사용방법 | |
| JPS59141519A (ja) | 制ガン作用を有する蛋白質 | |
| US4676983A (en) | Tumor cytostatic-citocidal factor from blood platelets | |
| KR870001433B1 (ko) | 적상적혈구(的狀赤血球) 붕괴인자의 제조 방법 | |
| NO850152L (no) | Fremgangsmaate ved fremstilling av human, endogen cancerregulerende faktor. | |
| JPS5888322A (ja) | 標的細胞障害性因子を含有する悪性腫瘍治療剤とその製造方法 | |
| KR960004028B1 (ko) | 면역증강제 조성물 | |
| NO842015L (no) | Immunstimulator | |
| JP2532025B2 (ja) | 新リンホカインｉｉｉを有効成分とする抗腫瘍作用を有するリンホカインの活性増強剤 | |
| KR890004692B1 (ko) | 항종양 생리학적 활성물질의 정제방법 |